Cargando…
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286746/ https://www.ncbi.nlm.nih.gov/pubmed/36053878 http://dx.doi.org/10.1002/ajh.26707 |
| _version_ | 1785061814718955520 |
|---|---|
| author | Jonas, Brian A. DiNardo, Courtney Fracchiolla, Nicola Pristupa, Alexander Ishizawa, Kenichi Jin, Jie Konopleva, Marina Ofran, Yishai Montesinos, Pau Kovacsovics, Tibor Jang, Jun‐Ho Kantarjian, Hagop Duan, Yinghui Potluri, Jalaja Werner, Michael Pratz, Keith W. |
| author_facet | Jonas, Brian A. DiNardo, Courtney Fracchiolla, Nicola Pristupa, Alexander Ishizawa, Kenichi Jin, Jie Konopleva, Marina Ofran, Yishai Montesinos, Pau Kovacsovics, Tibor Jang, Jun‐Ho Kantarjian, Hagop Duan, Yinghui Potluri, Jalaja Werner, Michael Pratz, Keith W. |
| author_sort | Jonas, Brian A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10286746 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley & Sons, Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102867462023-06-23 Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study Jonas, Brian A. DiNardo, Courtney Fracchiolla, Nicola Pristupa, Alexander Ishizawa, Kenichi Jin, Jie Konopleva, Marina Ofran, Yishai Montesinos, Pau Kovacsovics, Tibor Jang, Jun‐Ho Kantarjian, Hagop Duan, Yinghui Potluri, Jalaja Werner, Michael Pratz, Keith W. Am J Hematol Correspondences John Wiley & Sons, Inc. 2022-09-16 2022-11 /pmc/articles/PMC10286746/ /pubmed/36053878 http://dx.doi.org/10.1002/ajh.26707 Text en © 2022 The Authors. American Journal of Hematology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Correspondences Jonas, Brian A. DiNardo, Courtney Fracchiolla, Nicola Pristupa, Alexander Ishizawa, Kenichi Jin, Jie Konopleva, Marina Ofran, Yishai Montesinos, Pau Kovacsovics, Tibor Jang, Jun‐Ho Kantarjian, Hagop Duan, Yinghui Potluri, Jalaja Werner, Michael Pratz, Keith W. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study |
| title | Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study |
| title_full | Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study |
| title_fullStr | Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study |
| title_full_unstemmed | Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study |
| title_short | Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study |
| title_sort | use of cyp3ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the viale‐a study |
| topic | Correspondences |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286746/ https://www.ncbi.nlm.nih.gov/pubmed/36053878 http://dx.doi.org/10.1002/ajh.26707 |
| work_keys_str_mv | AT jonasbriana useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT dinardocourtney useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT fracchiollanicola useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT pristupaalexander useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT ishizawakenichi useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT jinjie useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT konoplevamarina useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT ofranyishai useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT montesinospau useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT kovacsovicstibor useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT jangjunho useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT kantarjianhagop useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT duanyinghui useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT potlurijalaja useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT wernermichael useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy AT pratzkeithw useofcyp3aiandimpactonoutcomesinpatientswithacutemyeloidleukemiatreatedwithvenetoclaxplusazacitidineinthevialeastudy |